Riskpilot← Back to searchSign inGet full accessVaccinum AB
ABActiveOrg 5592454234Fatbusgatan 18 AGeneral medical practice activities · NACE 8621Est. 20200 employees
Revenue 2025
SEK 82K
-39% vs 2024
EBITDA margin
-6.1%
+88% vs 2024
Equity ratio
34.1%
Financial strength
Net profit 2025
SEK 0
+100% vs 2024
| Revenue | SEK 82K | -39% |
| EBITDA | SEK -5K | +88% |
| Net profit | SEK 0 | +100% |
| Total assets | SEK 501K | -4% |
| Equity | SEK 171K | +0% |
| Employees | 0 | — |
Legal name
Vaccinum AB
Org number
5592454234
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
2 mars 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva vaccinationsverksamhet, hälso- och sjukvård samt forskning, utveckling och utbildning inom hälso- och sjukvård och därmed förenlig verksamhet.
Address
Fatbusgatan 18 A
Email
ann.gardulf@vaccinum.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 689 | 773 | 131 | 134 | 82 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 9 | 403 | −126 | −42 | −5 |
| Depreciation & amort. | −0 | −26 | −0 | −0 | −0 |
| EBIT | 9 | 377 | −126 | −42 | −5 |
| Net financials | — | — | 1 | 9 | 5 |
| Profit before tax | 9 | 377 | −125 | −34 | 0 |
| Tax | −3 | −78 | −0 | −0 | −0 |
| Net profit | 6 | 299 | −125 | −34 | 0 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 492 | 687 | 545 | 523 | 501 |
| Equity | 31 | 330 | 204 | 171 | 171 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 461 | 357 | 341 | 352 | 330 |
| Total debt | 461 | 357 | 341 | 352 | 330 |
EBITDA margin
-6.1%
This company
15.8%
Market median
-139% vs market
20212025
Equity ratio
34.1%
This company
38.2%
Market median
+11% vs market
20212025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20212025
Net profit margin
0.0%
This company
8.1%
Market median
-100% vs market
20212025
Asset turnover
0.16×
This company
1.12×
Market median
-86% vs market
20212025
Debt / equity
1.93×
This company
0.62×
Market median
-211% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-03-01 – 2021-04-30
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AE Chief Executive Officer | Chief Executive Officer | 2022 |
| Former (1) | ||
ME Audit | Audit | 2022 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (2) | ||
| Deputy Board Member | 2020 – 2022 | |
| Board of Directors | 2020 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Mega Care, Gardulf AB
Vaccinum AB Board members of Vaccinum AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Eva Bengtsson | Audit | 0 companies |
| Ann Elisabeth Maria Gardulf | Chief Executive Officer | 0 companies |
| Eva Margareta Eljans | Deputy Board Member | 0 companies |
| Kennet Tommy Oxelgren | Deputy Board Member | 0 companies |
| Anita Helena Berggren | Board of Directors | 0 companies |